Compare Adaptive Biotechnologies Corp (ADPT) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs CarMax, Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.88 (market cap $3.33B), while CarMax, Inc trades at $50.44 (market cap $7.24B). The key difference: CarMax, Inc is far larger — about 2.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | KMX | |
|---|---|---|
Market Cap | $3.33B | $7.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $68.38 |
52-Week Low | $10.24 | $30.88 |
Enterprise Value | $3.19B | $25.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CarMax (KMX) trades at $51.05, up 0.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 earnings that beat expectations, with revenue growth and cost control supporting a net income margin of 0.84%. Recent news highlights insider buying and a four-pillar turnaround strategy under new CEO Keith Barr, though margins remain under pressure.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating and $48.91 price target below current levels, but improving cash flow and strategic initiatives offer potential upside. Key risks include persistent margin compression, high debt levels, and execution challenges in a competitive used car market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
